Drug discovery

#Drug discovery #EMA #Funding #Huntington's disease #Monkeypox #Start-ups

This week in drug discovery (21 – 25 August)

News round-up for 21-25 August by DDW Editor Reece Armstrong A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. Covid researchers launch Monkeypox study   A new study investigating a potential treatment… Read More

#News

#Biosensors #Drug discovery #Webinar

Tips and Tricks on Obtaining Quality Data from Biosensors for Cell Signalling Assays

Tips and tricks on how to obtain and analyse high quality data from live cell, high throughput assays of signaling dynamics. Genetically encoded fluorescent biosensors enable continuous recording of cellular signaling in live cells. This breakthrough technology provides unprecedented, real-time measurements of signaling dynamics, which is emerging as a critical… Read More

Webinar date:
Brought to you by Agilent BioTek
#Webinars

#Drug discovery #Peptides #Pharmaceutical research #Proteins

Spider venom and heart attacks? Australian centre examines

Using deadly spider venom to treat heart attacks is one of many new discoveries currently being developed at a national research centre headquartered at The University of Queensland. The Australian Research Council (ARC) Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS) was launched this week at its… Read More

#Editor's Choice #News

#Drug discovery #High Throughput #Monoclonal antibodies #Webinar

Webinar: Applications in early monoclonal antibody discovery

Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to… Read More

#News

#Antibody reagents #Drug discovery #Monoclonal antibodies #Webinar

High throughput Octet BLI applications in early monoclonal antibody discovery

Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to… Read More

Webinar date:
Brought to you by Sartorius
#Webinars

#AI / data analytics / healthtech / informatics #Drug discovery #ELRIG #Lab automation

The automated lab and the human: DDW Tech Theatre at ELRIG Drug Discovery

DDW is delighted to announce that Adam Prosho, Global ILS Training Director, CBRE, will be taking part the Tech Theatre at ELRIG’s Drug Discovery 2022.   Supported by DDW, the Tech Theatre will feature a series of seminars focused on automation and technology for drug discovery. … Read More

#News

#CRISPR screening #Drug discovery #Library screening

Synthego launches cell libraries to improve CRISPR-based drug discovery  

Genome engineering company Synthego has launched a portfolio of Engineered Cell Libraries to help improve access to CRISPR-edited cells for direct use in functional screening assays.   The company’s Engineered Cell Libraries are designed to provide speed, scalability, and efficiency to accelerate the drug discovery… Read More

#News

#AI / data analytics / healthtech / informatics #Automation / robotics #Drug discovery #ELRIG

Informatics and data handling: DDW Tech Theatre at ELRIG Drug Discovery 

Samantha Kanza, Senior Enterprise Fellow, University of Southampton, will be speaking at the ELRIG Tech Theatre supported by DDW at this year’s ELRIG Drug Discovery 2022.  The Tech Theatre will feature a series of seminars focused on automation and technology for drug discovery.  The event… Read More

#News

#Cellular imaging #Drug discovery #Medicines Discovery Catapult

MDC and ZEISS look to advance microscopy for early drug discovery  

A new partnership has been formed between Medicines Discovery Catapult (MDC) and technology group ZEISS to improve drug discovery using advanced microscopy solutions.  The partnership will combine MDC’s expertise in cell biology and drug discovery with ZEISS’ microscope instrumentation and image analysis capabilities. In particular, the organisations… Read More

#News

#Biopharma #DNA #Drug discovery #Evonetix #Synthetic biology

Synthetic biology: Advancing drug discovery

This eBook, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big… Read More

#DDW eBooks

#Biopharma #Drug discovery #Evonetix #Organoids #Synthetic biology

Synthetic biology e-book out now  

This e-book, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big… Read More

#News

#DNA #Drug discovery #Gene sequencing #Synthetic biology

A different approach: reimagining biology

Listen to this article on the DDW Podcast: Evonetix is reimaging biology by developing a different approach to gene synthesis. Three key members of the team – Dr Raquel Sanches-Kuiper, Vice President of Technology, Dr Matthew Hayes, Chief Technology Officer and John Edgell, Head of Cloud Engineering… Read More

#Exclusive Content

#Drug discovery #Neurology #Small molecules

Sosei teams up with Abbvie on neurological drug discovery  

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases.   The agreement will see the companies combining their expertise and capabilities in neuroscience to discover and develop small molecules that modulate G protein-coupled… Read More

#News

Human brain
#Biologics / Biotechnology #Clinical trials #Drug discovery #Neurology

Calidi Biotherapeutics gets FDA go-ahead for US trial  

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma.  The phase I physician-sponsored clinical trial will take place at… Read More

#News

#AI / data analytics / healthtech / informatics #Automation / robotics #Drug discovery #ELRIG

DDW supports ELRIG at Drug Discovery 2022 

For the first time, a series of short seminars focused on automation will be available to visitors of Drug Discovery 2022 (4-5 Oct, London, UK).   The seminars will be held in a dedicated Tech Theatre, centrally located in the exhibition hall. DDW has been selected by ELRIG… Read More

#News